Prostatic Neoplasms, Castration-Resistant: all 84 studies

Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07863986
• A Study in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07719361Phase 1
• Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingNCT07717268Phase 2
• Pluvicto Real-world Investigation in Survival in Metastatic CRPCNot yet recruitingNCT07697989
• A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide TetraxetanRecruitingNCT07677267
• A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07677254
• Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand TherapyNot yet recruitingNCT07587814Not applicable
• Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate CancerNot yet recruitingNCT07376057
• A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate CancerRecruitingNCT07258407Phase 1/2
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07225946Phase 3
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingNCT07164443Phase 3
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingNCT06863272Phase 1/2
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate CancerRecruitingNCT06706921Phase 4
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)RecruitingNCT06353386Phase 1/2
• Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional ImagingRecruitingNCT06276465Phase 3
• A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
• Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06190899Phase 1/2
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerRecruitingNCT06067841Phase 1
• Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerRecruitingNCT05997615Phase 1
• HTL0039732 in Participants With Advanced Solid TumoursRecruitingNCT05944237Phase 1/2
• Actium-225-Prostate Specific Membrane Antigen Imaging & TherapyRecruitingNCT05902247Phase 1
• Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerRecruitingNCT05743621Phase 1
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)RecruitingNCT05519449Phase 1
• Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCRecruitingNCT05393791Phase 2
• 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)RecruitingNCT04868604Phase 1/2
• Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)RecruitingNCT04833517
• Fatty Acid Synthase Inhibition in Castration Refractory Prostate CancerRecruitingNCT04337580Phase 2
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
• The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate CarcinomaRecruitingNCT04104607Phase 1
• A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerCompletedNCT05968599Results posted
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 2Results posted
• Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT05520138Results posted
• A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerTerminatedNCT05169684Phase 2Results posted
• Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)TerminatedNCT04157088Phase 2Results posted
• Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate CancerCompletedNCT03822845Phase 2/3Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingNCT03748641Phase 3Results posted
• A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03431350Phase 2Results posted
• 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate CancerCompletedNCT03389451Phase 2/3Results posted
• 68Ga PSMA in Preprostatectomy PatientsCompletedNCT03388346Phase 2/3Results posted
• Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsCompletedNCT03248570Phase 2Results posted
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane RegimenCompletedNCT03016312Phase 3Results posted
• BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)CompletedNCT02204072Phase 1Results posted
• Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02057666Phase 3Results posted
• An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine CareCompletedNCT07843758
• A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT07047118Phase 2
• Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Temporarily not availableNCT06033001
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT05848011Phase 2
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1
• Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCWithdrawnNCT05191017Phase 1/2
• TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate CancerStatus unknownNCT05156450Phase 2
• A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruitingNCT05057013Phase 1/2
• Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.CompletedNCT04962919
• Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate CancerTerminatedNCT04918810Phase 2
• 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)No longer availableNCT04854369
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentTerminatedNCT04844749Phase 3
• Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2
• Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate CancerActive, not recruitingNCT04597411Phase 1
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTerminatedNCT04541225Phase 1
• Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT04428788Phase 1
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).TerminatedNCT04404140Phase 1
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedNCT04381832Phase 1/2
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)TerminatedNCT04249947Phase 1
• Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate CancerActive, not recruitingNCT04141709Not applicable
• Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)Status unknownNCT04126915
• Safety and Targeting of Anti-hk2 Antibody in mCRPCTerminatedNCT04116164Early Phase 1
• Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side EffectsCompletedNCT03927391Phase 4
• A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223CompletedNCT03563014
• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT03551782Phase 1
• Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review StudyWithdrawnNCT03325127
• Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC PatientsWithdrawnNCT03173859Phase 2
• A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate CancerCompletedNCT03017417Not applicable
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingNCT03016741Phase 4
• A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerWithdrawnNCT02906605Phase 2
• Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )CompletedNCT02899104
• Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)WithdrawnNCT02866916Phase 1
• Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone MetastasesCompletedNCT02803437
• Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate CancerCompletedNCT02625857Phase 1
• A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingNCT02592317Phase 1
• Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in GermanyCompletedNCT02450812
• Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone MetastasesCompletedNCT02398526
• Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate CancerStatus unknownNCT02254785Phase 2
• A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1

← Prostatic Neoplasms, Castration-Resistant overview